中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 药物发现与设计中心
The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells

文献类型：期刊论文

作者Chen, Gege1; Xu, Zhijian3; Chang, Gaomei1; Hou, Jun1; Hu, Liangning1; Zhang, Yiwen1; Yu, Dandan1; Li, Bo3; Chang, Shuaikang1; Xie, Yongsheng1
刊名ONCOLOGY REPORTS
出版日期2017-07
卷号38期号:1页码:488-496
ISSN号1021-335X
关键词pterostilbene multiple myeloma bortezomib-resistant cells apoptosis cell cycle histone deacetylase inhibitors
DOI10.3892/or.2017.5675
文献子类Article
英文摘要Multiple myeloma (MM) is an incurable hematologic malignancy because of its drug resistance. Pterostilbene (Pter) is found mainly in blueberries and grapes. The effects of Pter and its exact pharmacologic mechanisms on chemo-resistant myeloma are not known. Herein, we investigated the anti-myeloma activity of Pter in bortezomib-resistant cell line H929R and explored the related mechanism of action for the first time. We found that Pter inhibited proliferation of H929R cells and promoted apoptosis of the cells through a caspase-dependent pathway, loss of mitochondrial membrane potential, and activation of Akt and p38 mitogen-activated protein kinase (MAPK) signaling pathways. DNA damage and S-phase arrest might be involved in Pter-related toxicity in H929R cells. Pter and the histone deacetylase inhibitors panobinostat or vorinostat inhibited proliferation of H929R cells in a synergistic manner. These data supported that Pter might be a promising natural compound for relapsed/refractory myeloma therapy, especially against myeloma resistant to bortezomib chemotherapy.
WOS关键词HISTONE DEACETYLASE INHIBITORS ; MULTIPLE-MYELOMA ; CYCLE CHECKPOINTS ; LEUKEMIA-CELLS ; CANCER CELLS ; APOPTOSIS ; RESVERATROL ; AUTOPHAGY ; MITOCHONDRIA ; PANOBINOSTAT
资助项目National Natural Science Foundation of China[81372391] ; National Natural Science Foundation of China[81570190] ; National Natural Science Foundation of China[81529001] ; National Natural Science Foundation of China[81302699] ; National Natural Science Foundation of China[31271496] ; National Natural Science Foundation of China[81600174] ; National Natural Science Foundation of China[81300443] ; 'Personalized Medicines-Molecular Signature-based Drug Discovery and Development', Strategic Priority Research Program of the Chinese Academy of Sciences[XDA12020309]
WOS研究方向Oncology
语种英语
出版者SPANDIDOS PUBL LTD
WOS记录号WOS:000404089500055
源URL[http://119.78.100.183/handle/2S10ELR8/272593]  
专题药物发现与设计中心
通讯作者Shi, Jumei; Zhu, Weiliang
作者单位1.Tongji Univ, Sch Med, Shanghai Peoples Hosp 10, Dept Hematol, 301 Yanchang Rd, Shanghai 200072, Peoples R China;
2.Tongji Univ, Coll Life Sci & Technol, Shanghai 200092, Peoples R China
3.Chinese Acad Sci, Shanghai Inst Mat Med, Drug Discovery & Design Ctr, CAS Key Lab Receptor Res, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China;
推荐引用方式
GB/T 7714		 Chen, Gege,Xu, Zhijian,Chang, Gaomei,et al. The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells[J]. ONCOLOGY REPORTS,2017,38(1):488-496.
APA Chen, Gege.,Xu, Zhijian.,Chang, Gaomei.,Hou, Jun.,Hu, Liangning.,...&Zhu, Weiliang.(2017).The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells.ONCOLOGY REPORTS,38(1),488-496.
MLA Chen, Gege,et al."The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells".ONCOLOGY REPORTS 38.1(2017):488-496.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。